ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,272.01
0.29%
Dow Jones
39,112.16
-0.76%
Gold vs US Dollar
2,315.64
-0.22%
Brent Oil
84.935
0.89%
Bitcoin
61,242.58
-0.92%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NYSE
  6. Organon and Co (OGN)

  7. Organon and Co (OGN) News

Organon (OGN)

Organon and Co
Date:
Sort by:
 Showing the most relevant articles for your search:NYSE:OGN
DateTimeSourceHeadlineSymbolCompany
11/06/202420:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
11/06/202420:16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
11/06/202420:16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
06/06/202412:00Edgar (US Regulatory)Form 8-K - Current reportNYSE:OGNOrganon and Co
24/05/202418:59Business WireEuropäische Arzneimittel-Agentur (EMA) validiert Einreichungen von Henlius und Organon für den Prolia ® und Xgeva ® (Denosumab) Biosimilar-Kandidaten HLX14NYSE:OGNOrganon and Co
24/05/202418:59Business WireL’Agence européenne des médicaments (EMA) entérine les dépôts de Henlius et d’Organon pour le candidat biosimilaire HLX14 de Prolia ® et Xgeva ® (denosumab)NYSE:OGNOrganon and Co
24/05/202416:29Business Wire欧州医薬品庁（EMA）、ヘンリウスとオルガノンによるProlia ® およびXgeva ® （デノスマブ）バイオシミラー候補HLX14を認証NYSE:OGNOrganon and Co
24/05/202411:00Business WireEuropean Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14NYSE:OGNOrganon and Co
17/05/202421:15Edgar (US Regulatory)Form 8-K - Current reportNYSE:OGNOrganon and Co
08/05/202401:20Business WireOrganon Announces Pricing of $1.0 Billion Senior Notes OfferingNYSE:OGNOrganon and Co
07/05/202421:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
07/05/202421:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
07/05/202421:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
07/05/202421:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
07/05/202421:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
07/05/202421:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
07/05/202421:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
07/05/202412:58Business WireOrganon Announces Proposed $1.0 Billion Senior Notes OfferingNYSE:OGNOrganon and Co
02/05/202412:30Business WireOrganon Reports Results for the First Quarter Ended March 31, 2024NYSE:OGNOrganon and Co
09/04/202413:13Business WireProlia ® とXgeva ® （デノスマブ）との第3相比較臨床試験でバイオシミラー候補HLX1​​4が主要評価項目を達成NYSE:OGNOrganon and Co
08/04/202419:31Business WireKlinische Phase-3-Vergleichsstudie zwischen Prolia ® und Xgeva ® (Denosumab) - Biosimilar-Kandidat HLX14 erreicht primäre EndpunkteNYSE:OGNOrganon and Co
08/04/202419:31Business WireL'essai clinique comparatif de phase 3 du candidat biosimilaire de Prolia ® et de Xgeva ® (denosumab) HLX14 remplit les critères d'évaluation primairesNYSE:OGNOrganon and Co
08/04/202411:15Business WireOrganon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024NYSE:OGNOrganon and Co
08/04/202411:00Business WirePhase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary EndpointsNYSE:OGNOrganon and Co
08/03/202414:01PR Newswire (Canada)On International Women's Day, Organon Canada is encouraging businesses to Invest in HER and help address gender inequities through women's healthNYSE:OGNOrganon and Co
08/03/202414:01PR Newswire (Canada)À l'occasion de la Journée internationale des femmes, Organon Canada encourage les entreprises à Investir en elle et à lutter contre les inégalités entre les genres par la santé des femmesNYSE:OGNOrganon and Co
01/03/202421:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
01/03/202421:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
01/03/202421:22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
01/03/202421:22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
 Showing the most relevant articles for your search:NYSE:OGN

Your Recent History

USOTC
ADHG
Ando (GM)
EU
2656T
2656T
TSXV
TTL.P
AMEX
SING
SinglePoint
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved